A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer

Journal of Gastrointestinal Surgery

Volumn 15, Issue 11, 2011, Pages 2059-2069

  Laurence, Jerome Martin ^a,b,c   Tran, Peter Duy ^d   Morarji, Kavita ^d   Eslick, Guy D ^a   Lam, Vincent Wai To ^a,c   Sandroussi, Charbel ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

Author keywords

Chemoradiotherapy; Meta analysis; Neoadjuvant treatment; Pancreatic neoplasms; Systematic review

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ARTICLE; CARCINOMA; HUMAN; META ANALYSIS; MORTALITY; PANCREAS RESECTION; PANCREAS TUMOR; SURVIVAL;

CARCINOMA; CHEMORADIOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 80255122607     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1659-7     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 1979; 189 (2): 205-208.
3. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80 (10): 751-755.
4. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19 (9): 1592-1599.
5. Brunner TB, Grabenbauer GG, Meyer T, et al. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 2007; 7: 41.
6. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7 (4): e1000267.
7. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010; 17 (1): 194-205.
8. Delpero JR, Turrini O. [Locally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resection]. Cancer Radiother 2006; 10 (6-7): 462-470.
9. Higgins JPTGS. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 02, 2009.
10. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560.
11. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20 (4): 641-654.
12. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315 (7109): 629-634.
13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17 (24): 2815-2834.
14. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
15. Al-Sukhun S, Zalupski MM, Ben-Josef E, et al. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. Am J Clin Oncol 2003; 26 (6): 543-549.
16. Allendorf JD, Lauerman M, Bill A, et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg 2008; 12 (1): 91-100.
17. Bruckner HW, Kalnicki S, Dalton J, et al. Survival after combined modality therapy for pancreatic cancer. J Clin Gastroenterol 1993; 16 (3): 199-203.
18. Chao C, Hoffman JP, Ross EA, et al. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience. Am Surg 2000; 66 (4): 378-385; discussion 386.
19. Golcher H, Brunner T, Grabenbauer G, et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 2008; 34 (7): 756-764.
20. Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008; 206 (3): 451-457.
21. Ishikawa O, Ohigashi H, Imaoka S, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg 1994; 129 (10): 1075-1080.
22. Jessup JM, Steele G, Jr., Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993; 128 (5): 559-564.
23. Kim HJ, Czischke K, Brennan MF, et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg 2002; 6 (5): 763-769.
24. Lind PA, Isaksson B, Almstrom M, et al. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol 2008; 47 (3): 413-420.
25. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006; 13 (9): 1201-1208.
26. Pendurthi TK, Hoffman JP, Ross E, et al. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 1998; 64 (7): 686-692.
27. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001; 5 (2): 121-130.
28. Piperdi M, McDade TP, Shim JK, et al. A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database. HPB (Oxford) 2010; 12 (3): 204-210.
29. Satoi S, Yanagimoto H, Toyokawa H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009; 38 (3): 282-288.
30. Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000; 89 (2): 314-327.
31. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15 (3): 928-937.
32. Vento P, Mustonen H, Joensuu T, et al. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol 2007; 13 (21): 2945-2951.
33. Grading systems and levels of evidence and grade of recommendation. SIGN guideline development handbook: SIGN 50.
34. White RR, Kattan MW, Haney JC, et al. Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol 2006; 13 (11): 1485-1492.
35. Abrams RA, Lowy AM, O'Reilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16 (7): 1751-1756.
36. Hoffman JP. Status of neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am 2010; 19 (2): 411-418.
37. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16 (7): 1727-1733.
38. Sasson AR, Wetherington RW, Hoffman JP, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer 2003; 34 (2-3): 121-128.
39. Ishikawa O, Ohigashi H, Imaoka S, et al. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy. Arch Surg 1991; 126 (7): 885-889.